Quinolinium salts and derivatives thereof for treating flavivirus infection
Quinolinium salts and derivatives effectively inhibit Flavivirus NS2B-NS3 proteases, addressing the need for improved treatments against Flavivirus infections by targeting the enzymes in Zika, Dengue, and West Nile Viruses, providing a potential therapeutic solution for these mosquito-borne diseases.
Patent Information
- Application Number
- PCT/US2024/031662
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-05-30
- Filing Date
- 2024-05-30
- Publication Date
- 2024-12-05
AI Technical Summary
Current treatments lack effective solutions for inhibiting Flavivirus infections, particularly for diseases like Dengue, Zika, and West Nile viruses, which are increasingly prevalent and pose significant public health threats due to their mosquito-borne transmission and severe health consequences.
Development of quinolinium salts and derivatives, specifically compounds of Formula I and II, which are designed to inhibit NS2B-NS3 proteases of Flaviviruses, formulated into pharmaceutical compositions for oral or intravenous administration to treat or prevent Flavivirus infections.
The compounds demonstrate significant inhibition of NS2B-NS3 protease activity in Zika, Dengue, and West Nile Viruses, offering a promising therapeutic approach to reduce the risk and treat Flavivirus infections effectively.
Smart Images

Figure IMGF000003_0001 
Figure IMGF000004_0001 
Figure IMGF000006_0001
Abstract
Description
QUINOLINIUM SALTS AND DERIVATIVES THEREOF FOR TREATING FLAVIVIRUS INFECTIONGOVERNMENT LICENSE RIGHTS
[0001] This invention was made with government support under (NIH GRANT Number: 5R43AI145617) awarded by (National Institutes of Health in the United States). The government has certain rights in the invention.CROSS-REFERENCE TO RELATED APPLICATION
[0002] This patent application claims priority to U.S. Provisional Patent Application No. 63 / 505,019, filed on May 30, 2023, which is herein incorporated by reference in its entirety.FIELD
[0003] The present disclosure is related to novel quinolinium salts and derivatives thereof, methods of making and using the same, such as for inhibiting NS2B-NS3 proteases of Flaviviruses and for treating or reducing the risk of infectious diseases and / or conditions related to NS2B-NS3 proteases.BACKGROUND
[0004] Flavivirus is a genus of viruses in the family Flaviviridae. Viruses in this family include Dengue virus (DNV) serotypes 1-4, West Nile virus (WNV), Zika virus (ZKV), Yellow Fever virus (YFV) and Japanese encephalitis virus (JEV). Also known as arboviruses due to their ability to be transmitted by the bite from an infected mosquito, these viruses are the etiologic agents of many debilitating diseases affecting the human population worldwide. These mosquito borne diseases have been emerging and re-emerging and concomitantly with increasing incidences and expanding geographical range. DNV is the fastest spreading arboviral disease and is one of the top ten threats to global health in 2019. Approximately 400 million people are infected causing 22,000 deaths worldwide each year. Similarly, the frequency, severity, and geographic range of WNV outbreaks have also increased. WNV infection can result in meningitis, encephalitis, or paralysis leading to -10% mortality among hospitalized patients and is considered the most important causative agent of viral encephalitis worldwide. The latest example of another arboviral disease reemergence and expansion is the introduction of ZKV in the American continent, characterized by a mild febrile condition in adults. Alarmingly, ZKV infection in pregnant women has been linked to abortion, stillbirth, or infants bom preterm with the Congenital Zika Syndrome, characterized by microcephaly,cerebral calcifications, ventriculomegaly, and arthrogryposis. In adults ZKV infection can cause neuronal pathology such as Guillain-Barre syndrome. The World Health Organization (WHO) has recently revised its assessment of ZKV and now considers ZKV infection and associated pathologies a significant enduring public health challenge requiring immediate action.SUMMARY OF VARIOUS ASPECTS
[0005] In one embodiment, the present disclosure provides a compound having Formula I orII, a pharmaceutically acceptable salt, N-oxides, tautomers, hydrates, isotopes, or prodrugs thereof, or a mixture thereofFormula I Formula II wherein,R is C1to C12alkyl, C2to C12alkenyl, C2to C12alkynyl, C2to C12substituted alkyl, C2to C12substituted alkenyl, or C2to C12substituted alkynyl;R1and R2 are one of more groups independently selected from H, halo, alkyl, alkoxy, cyano, nitro, CO2R4, C(O)NR4R5, -CH=NR4, -NR4R5, or -N= R6, wherein,R4and R5are independently C1to C12alkyl, C2to C12alkenyl, C2to C12alkynyl, C2to C12substituted alkyl, C2to C12substituted alkenyl, C2to C12substituted alkynyl, or -NR4R5is heterocyclic, substituted heterocyclic and cyclic C2to C7heteroalkylene or substituted cyclic C2to C7heteroalkyne; andR6is hydrogen, oxygen, C1to C12alkyl or C1to C12substituted alkyl; R3is H or C1to C2alkyl.
[0006] In another embodiment, the present disclosure provides for a pharmaceutical composition comprising any of the compounds described herein. In particular embodiments, the composition is a tablet (e.g., suitable for oral administration) or a liquid (e.g., suitable for an intravenous administration).
[0007] In another embodiment, the present disclosure provides a method of preparing the compound of Formula I or Formula II.
[0008] In yet another embodiment, the present disclosure provides a method of treating and / or reducing the risk of Flavivirus infection in a subject by administrating a compound of Formula I or Formula II to a subj ect in need thereof, or a pharmaceutical composition (e.g., tablet, liquid) comprising a compound of Formula I or Formula II to a subject in need thereof.BRIEF DESCRIPTION OF THE DRAWINGS
[0009] FIG. 1 presents the activity of CPD5254 inhibiting Zika Virus as measured in Example 5.
[0010] FIG. 2 presents the activity of CPD5254 inhibiting West Nile Virus as measured in Example 5.
[0011] FIG. 3 presents the activity of CPD5254 inhibiting Dengue Virus as measured in Example 5.DETAILED DESCRIPTION
[0012] The present disclosure provides a compound having Formula I or II, a pharmaceutically acceptable salt, N-oxides, tautomers, hydrates, isotopes, or prodrugs thereof, or a mixture thereof:wherein,R is C1to C12alkyl, C2to C12alkenyl, C2to C12alkynyl, C2to C12substituted alkyl, C2to C12substituted alkenyl, or C2to C12substituted alkynyl;R1and R2 are one of more groups independently selected from H, halo, alkyl, alkoxy, cyano, nitro, CO2R4, C(O)NR4R5, -CH=NR4, -NR4R5, or -N=R6, wherein,R4and R5are independently C1to C12alkyl, C2to C12alkenyl, C2to C12alkynyl, C2to C12substituted alkyl, C2to C12substituted alkenyl, C2to C12substituted alkynyl, or -NR4R5is heterocyclic, substituted heterocyclic and cyclic C2to C7heteroalkylene or substituted cyclic C2to C7heteroalkyne;R6is hydrogen, oxygen, C1to C12alkyl or C1to C12substituted alkyl;R3is H or C1to C2alkyl; andX is a halide, alkyl sulfonate, trihaloalkyl sulfonate, aryl sulfonate, or alkylsulfate.
[0013] In another embodiment, the present disclosure provides thatR is C1to C7alkyl, C7to C18phenylalkyl; andR1and R2 are one of more groups independently selected from H, F, Cl, Br, nitro, amine, CH3, OMe, CF3, O CF3, C1to C12alkyl, C1to C12alkenyl, carboxylic acid or ester thereof;R4and R5are independently, C1to C6alkyl, or C1to C6substituted alkyl; and X is a halide, methanesulfonate, trifluoromethanesulfonate, toluenesulfonate, or methylsulfate.
[0014] Alternatively, in a particular embodiment, -NR4R5is independently selected form a heterocyclic ring of 4 to 8 atoms, containing 0 to 3 additional heteroatoms selected from N, O and S as well as the groups C=O or C=NR6, and the heterocyclic ring may be substituted.
[0015] In another particular embodiment, the heterocyclic ring for -NR4R5includes, but not limited to, morpholine-4-yl, piperazine- 1-yl, 3 -oxopiperazine- 1-yl, and 1 -homopiperazine- lyl.
[0016] In a particular embodiment,R is C1to C12alkyl;R1and R2 are one of more groups independently selected from H, halo, alkyl, alkoxy, or cyano;R3is H or C1to C2alkyl.R4and R5are independently H or C1to C12alkyl; andR6is hydrogen or oxygen.
[0017] In a further particular embodiment,R is CH3, CH2CH3, CH2CH2CH3or CH(CH3)2;RI and R2 are one of more groups independently selected from H, fluoro, chloro, CH3, CH2CH3, CH2CH2CH3or CH(CH3)2, OCH3, OCH2CH3, OCH2CH2CH3or OCH(CH3)2, or CN;R3is H, CH3, CH2CH3, CH2CH2CH3or CH(CH3)2.R.4 and R5are independently H, CH3, CH2CH3, CH2CH2CH3or CH(CH3)2; andR6is oxygen.
[0018] In an alternate embodiment, the compound of Formula I or Formula II are selected from:
[0019] The present disclosure further provides a pharmaceutical composition comprising a compound having Formula I or II, a pharmaceutically acceptable salt, N-oxides, tautomers, hydrates, or isotopes thereof, or a mixture thereof, and a pharmaceutically acceptable carrier. In other aspects, the present disclosure provides a pharmaceutical composition comprising any of the compounds described herein. In other aspects, the pharmaceutical composition is a tablet (e.g., for oral administration) such as for the use of preventing / reducing the risk of a flavivirus infection in an individual. In other aspects, the pharmaceutical composition is a liquid (e.g., for intravenous administration) such as for the treatment of an individual infected by a flavivirus.
[0020] The present disclosure also provides for methods for preparing the compounds described herein.
[0021] Reaction Schemes A-C illustrate exemplary methods for obtaining the compounds of Formula I and II:
[0022] First, a compound of Formula 3 and R-X, such as alkyl trifluoromethanesulfonate, react to form a compound of Formula 4 as shown in Reaction Scheme A:
[0023] Next, the compound of Formula 4 reacts with a compound of Formula 5 to form a compound of Formula 1 as shown in Reaction Scheme B:
[0024] Alternatively, the compound of Formula 4 reacts with a compound of Formula 6 to form a compound of Formula II as shown in Reaction Scheme C:wherein,R is C1to C12alkyl, C2to C12alkenyl, C2to C12alkynyl, C2to C12substituted alkyl, C2to C12substituted alkenyl, or C2to C12substituted alkynyl;R1and R2 are one of more groups independently selected from H, halo, alkyl, alkoxy, cyano, nitro, CO2R4, C(0)NR4R5, -CH=NR4, -NR4R5, or -N= R6, wherein,R4and R5are independently C1to C12alkyl, C2to C12alkenyl, C2to C12alkynyl, C2to C12substituted alkyl, C2to C12substituted alkenyl, C2to C12substituted alkynyl, or -NR4R5is heterocyclic, substituted heterocyclic and cyclic C2to C7heteroalkylene or substituted cyclic C2to C7heteroalkyne;R6is hydrogen, oxygen, C1to C12alkyl or C1to C12substituted alkyl;R3is H or C1to C2alkyl; andX is a halide, alkyl sulfonate, trihaloalkyl sulfonate, aryl sulfonate, or alkylsulfate.
[0025] In a particular embodiment,R is C1to C7alkyl, C7to C18phenylalkyl;R1and R2 are H or at least one or more groups from F, Cl, Br, nitro, amine, CH3, OMe, CF3, OCF3, C1to C12alkyl, C1to C12alkenyl, Carboxylic acid, ester, etc.;R3is H or C1to C2alkyl.
[0026] Another embodiment of the present disclosure provides methods of treating and / or reducing the risk of a flavivirus infection, comprising: administering a pharmaceutical composition comprising a compound having Formula I or II, a pharmaceutically acceptable salt, N-oxides, tautomers, hydrates, isotopes, or prodrugs thereof, or a mixture thereof, and a pharmaceutically acceptable carrier to a subject in need thereof. In other aspects, the present disclosure provides for methods of treating and / or reducing the risk of a flavivirus infection, comprising: administering any of the compounds described herein to a subject in need thereof. In other aspects, the pharmaceutical composition is a tablet (e.g., for oral administration) such as for the use of preventing / reducing the risk of a flavivirus infection in an individual. For example, the pharmaceutical composition (e.g., tablet) can be administered to an individual prior to (e.g., one or more days before) traveling to a country at risk for flavivirus infection. In other aspects, pharmaceutical composition is a liquid (e.g., for intravenous administration) such as for the treatment of an individual already infected by a flavivirus. In other aspects, the pharmaceutical composition (e.g., tablet, liquid) can be administered to an individual prior to (e.g., one or more days before) traveling to a country at risk for flavivirus infection, during the time of traveling, and / or after returning from traveling in country where flaviviruses are presentor known to be present (e.g., one or more days after returning) for treating and / or preventing / reducing the risk of a flavivirus infection.
[0027] In any of the methods described herein, the flavivirus may be West Nile Virus, Zika Virus, Dengue Virus, Yellow Fever Virus, or Japan encephalitis virus. In other particular embodiments, the Flavivirus is Dengue Virus serotype DEN-1, Dengue Virus serotype DEN- 2, Dengue Virus serotype DEN-3, or Dengue Virus serotype DEN-4.
[0028] For any structure disclosed herein, the scope of a compound also includes any tautomer which may be formed. Unless otherwise indicated, reference to a compound should be construed broadly to include pharmaceutically acceptable salts, tautomers, alternate solid forms, non-covalent complexes, and combinations thereof, of a chemical entity of the depicted structure or chemical name.
[0029] A pharmaceutically acceptable salt is any salt of the parent compound that is suitable for administration to an animal or human. A pharmaceutically acceptable salt also refers to any salt which may form in vivo as a result of administration of an acid, or another salt. A salt comprises one or more ionic forms of the compound, such as a conjugate acid or base, associated with one or more corresponding counter-ions. Salts can form from or incorporate one or more deprotonated acidic groups (e.g. carboxylic acids), one or more protonated basic groups (e.g. amines), or both (e.g. zwitterions).
[0030] Tautomers are isomers that are in rapid equilibrium with one another. For example, tautomers may be related by transfer of a proton, hydrogen atom, or hydride ion.
[0031] Unless stereochemistry is explicitly depicted, a structure is intended to include every possible stereoisomer, both pure or in any possible mixture.
[0032] A prodrug is a compound which is converted to a therapeutically active compound after administration. For example, conversion may occur by the removal of a biologically labile group. Prodrug preparation is well known in the art. For example, “Prodrugs and Drug Delivery Systems,” which is a chapter in Richard B. Silverman, Organic Chemistry of Drug Design and Drug Action, 2d Ed., Elsevier Academic Press: Amsterdam, 2004, pp. 496-557, provides further detail on the subject.EXAMPLES
[0033] As depicted in the Examples below, in certain exemplary embodiments, compounds are prepared according to the following general procedures. It will be appreciated that, although the general methods depict the synthesis of certain compounds of the present invention, the following general methods, and other methods known to one of ordinary skill in the art, can beapplied to all compounds and subclasses and species of each of these compounds, as described herein.Example 1: General
[0034] Unless otherwise indicated, all anhydrous solvents were commercially obtained (Sigma-Aldrich) and stored in Sure-seal bottles under nitrogen. All other reagents and solvents were purchased from Combi-block, San Diego, USA as the highest grade available and used without further purification. Thin-layer chromatography (TLC) analysis of reaction mixtures was performed using Merck silica gel 60 F254 TLC plates and visualized using ultraviolet light. NMR spectra were recorded on Bruker 500 MHz instrument (NuMega Labs). Chemical shifts (S) are reported in parts per million (ppm) referenced to 'H (Me4Si at 0.00). Coupling constants (J) are reported in Hz throughout. Mass spectral data were acquired on Shimadzu LCMS-2010EV for low resolution, and on an Agilent ESI-TOF for either high or low resolution. Purity of all compounds was obtained in a HPLC Breeze from Waters Co. using an Atlantis T3 3 pm 4.6x150 mm reverse phase column. The eluant was a linear gradient with a flow rate of 1 ml / minute from 95% A and 5% B to 5% A and 95% B in 15 minutes followed by 5 minutes at 100% B (Solvent A: H2O with 0.1% TFA; Solvent B: acetonitrile with 0.1% TFA). The compounds were detected at λ=254 nm or 214 nm. The purity of key compounds was established by elemental analysis as performed on a Perkin Elmer series 11-2400.
[0035] To a stirred solution of 2-methylquinoline (1.38 mmol) in anhydrous dichloromethane (7 mL) at room temperature was added methyl trifluoromethanesulfonate (1.52 mmol) dropwise. The solution was stirred for 16 hours. Dichloromethane was removed by rotavapor at 30°C, the resulted white solid was washed with hexane and hexane and ethyl acetate mixture, and the residue was dried under vacuum to yield Compound 4 in 94-96% yield.Example 3: Procedure for the Preparation of a Compound of Formula I
[0036] To a solution of 1,2-dimethylquinolinium triflate (0.571 mmol) and 8- hydroxyquinoline-5-carbaldehyde (0.571 mmol) in anhydrous methanol (1 mL) was added piperidine (1-2 drops), the reaction mixture was refluxed for 7 hours, cooled to room temperature, and filtered to collect the solid using vacuum filtration. The solid was washed with ethyl acetate (2 mL) and little methanol, dried under high vacuum to obtain the Compound 1 in 30-70% yield. Optionally the resulting solid can be further purified by column chromatography or equivalent method. The structure was confirmed by NMR.Example 4: Procedure for the Preparation of a Compound of Formula II
[0037] To a solution of 1,2-dimethylquinolinium triflate (0.571 mmol) and 8- hydroxyquinoline-4-carbaldehyde (0.571 mmol) in anhydrous methanol (1 mL) was added piperidine (1-2 drops), the reaction mixture was refluxed for 7 hours, cooled to room temperature, and filtered to collect the solid using vacuum filtration. The solid was washed with ethyl acetate (2 mL) and little methanol, dried under vacuum. This compound was purified by silica gel column chromatography (12 g) to obtain purified Compound 2 in 30-40% yield. The structure was confirmed by NMR.
[0038] The following Examples provide NMR data of compounds of Formula I and Formula II prepared by the experimental procedure provided in Examples 2-4 using the corresponding quinoline carbaldehyde.
[0039] Example 4-1: 2-[2-(8-Hydroxyquinolin-5-yl)-vinyl]-l-methylquinolinium trifluoromethanesul fonate (CPD 5245)'H NMR (500 MHz, DMSO-d3); δ(ppm): 9.15 (d, J = 10 Hz, 1H), 9.02 (d, J = 5 Hz, 1H), 8.96 (d, J = 5 Hz, 1H), 8.90-8.85 (m, 2H), 8.55-8.52 (m, 2H), 8.33 (d, J = 10 Hz, 1H), 8.17 (t, J = 5 Hz, 1H), 7.95-7.91 (m, 1 H), 7.76 (dd, J = 10, 5 Hz, 1H), 7.28 (d, J = 10 Hz, 1H), 4.57 (s, 3H); Mass: 313 (M + 1, free base).
[0040] Example 4-2: 7-Chloro-2-[2-(8-hydroxyquinolin-5-yl)-vinyl]-l-methylquinolinium trifluoromethanesulfonate (CPD5247)1H NMR (500 MHz, DMSO-d3); δ(ppm): 9.07 (d, J = 5 Hz, 1H), 8.82 (d, J = 5 Hz, 1H), 8.75 (d, J = 15 Hz, 1H), 8.61 (d, J = 5 Hz, 1H), 8.49 (m, 2H), 8.32 (s, 1H), 8.09 (d, J = 10 Hz, 1H), 7.73 (d, J = 10 Hz, 1H), 7.67 (m, 1 H), 7.42 (d, J = 9 Hz, 1H), 6.95 (d, J = 10 Hz, 1H), 4.24 (s, 3H); Mass: 347 (M + 1, free base).
[0041] Example 4-3: 2-[2-(8-Hydroxyquinolin-4-yl)-vinyl]-l-methylquinolinium trifluoromethanesulfonate (CPD5248)'H NMR (500 MHz, DMSO-d3); δ(ppm): 9.99 (s, 1H), 9.24 (d, J = 10 Hz, 1H), 9.01 (d, J = 5 Hz, 1H), 8.85 (d, J = 10 Hz, 1H), 8.78 (d, J = 15 Hz, 1H), 8.64 (d, J = 10 Hz, 1H), 8.45 (d, J = 5 Hz, 1H), 8.28-8.22 (m, 3H), 8055-8.01 (m, 2H), 7.60 (t, J = 10 Hz, 1H), 7.21 (d, J = 5 Hz, 1H), 4.66 (s, 3H); Mass: 313 (M + 1, free base).
[0042] Example 4-4: 6-Chloro-2-[2-(8-hydroxyquinolin-5-yl)-vinyl]-l-methylquinolinium trifluoromethanesulfonate (CPD5249)'H NMR (500 MHz, DMSO-d3); δ(ppm): 9.16 (d, J = 5 Hz, 1H), 8.97 (d, J = 5 Hz, 1H), 8.95-8.90 (m, 3H), 8.57 (m, 2H), 8.32 (s, 1H), 8.48 (d, J = 2 Hz, 1H), 7.77 (dd, J = 5, 10 Hz, 1H), 7.29 (d, J = 5 Hz, 1H), 4.56 (s, 3H); Mass: 347 (M + 1, free base).
[0043] Example 4-5: 6-Fluoro-2-[2-(8-hydroxyquinolin-5-yl)-vinyl]-l-methylquinolinium trifluoromethanesul fonate (CPD 5250)1H NMR (500 MHz, DMSO-d3); δ(ppm): 9.15 (d, J = 10 Hz, 1H), 8.97 (m, 2H), 8.90 (m, 2H), 8.63 (dd, J = 5, 10 Hz, 1H), 8.55 (d, J = 5 Hz, 1H), 8.19 (dd, J = 5, 10 Hz, 1H), 8.11 (m, 1H), ), 7.92 (d, J = 15 Hz, 1H), ), 7.69 (dd, J = 5, 7.5 Hz, 1H), ), 7.29 (d, J = 10 Hz, 1H), 4.59 (s, 3H); Mass: 331 (M + 1, free base).
[0044] Example 4-6: 2-[2-(8-Hydroxyquinolin-5-yl)-vinyl]-l,6-dimethylquinolinium trifluoromethanesul fonate (CPD 5254)'H NMR (500 MHz, DMSO-d3); δ(ppm): 9.13 (d, J = 10 Hz, 1H), 8.97 (d, J = 5 Hz, 1H), 8.92 (d, J = 10 Hz, 1H), 8.85-8.80 (m, 1H), 8.50 (d, J = 10 Hz, 1H), 8.45 (d, J = 5 Hz, 1H), 8.11 (s, 1H), 8.01 (d, J = 10 Hz, 1H), 7.90 (d, J = 15 Hz, 1H), 7.75 (dd, J = 5, 10 Hz, 1H), 7.28 (d, J = 10 Hz, 1H), 4.56 (s, 3H), 2.60 (s, 3H); Mass: 327 (M + 1, free base).
[0045] Example 4-7: 4-Cyano-2-[2-(8-hydroxyquinolin-5-yl)-vinyl]-l-methylquinolinium trifluoromethanesul fonate (CPD 5255)'H NMR (500 MHz, DMSO-d3); δ(ppm): 9.60 (s, 1H), 9.07 (d, J = 10 Hz, 1H), 8.96 (m, 2H), 8.69 (d, J = 5 Hz, 1H), 8.33 (s, 1H), 8.02 (m, 2H), 7.86 (m, 2H), 7.30 (s, 1H), 6.76 (s, 1H), 4.60 (s, 3H); Mass: 338 (M + 1, free base).
[0046] Example 4-8: 2-[2-(8-Hydroxyquinolin-5-yl)-vinyl]-8-methoxy-l-methylquinolinium trifluoromethanesul fonate (CPD 5256)'H NMR (500 MHz, DMSO-d3); δ(ppm): 9.14 (d, J = 10 Hz, 1H), 8.97 (m, 2H), 8.86 (d, J = 15 Hz, 1H), 8.79 (d, J = 10 Hz, 1H), 8.46 (d, J = 5 Hz, 1H), 7.88-7.76 (m, 3H), 7.75- 7.72 (m, 2H), 7.29 (d, J = 10 Hz, 1H), 4.58 (s, 3H), 4.11 (s, 3H); Mass: 343 (M + 1, free base).
[0047] Example 4-9: 7-Fluoro-2-[2-(8-hydroxyquinolin-5-yl)-vinyl]-l-methylquinolinium trifluoromethanesulfonate (CPD5257)1H NMR (500 MHz, DMSO-d3); δ(ppm): 9.17 (s, 1H), 9.03-8.90 (m, 4H), 8.51 (m, 3H), 7.91 (m, 2H), 7.78 (s, 1H), 4.53 (s, 3H); Mass: 331 (M + 1, free base).
[0048] Example 4-10: 2-[2-(8-Hydroxyquinolin-4-yl)-vinyl]-l,6-dimethylquinolinium trifluoromethanesulfonate (CPD5258)1H NMR (500 MHz, DMSO-d3); δ(ppm): 9.97 (s, 1H), 9.12 (d, J = 5 Hz, 1H), 9.00 (d, J = 5 Hz, 1H), 8.79 (d, J = 5 Hz, 1H), 8.78 (d, J = 15 Hz, 1H), 8.55 (d, J = 5 Hz, 1H), 8.20 (m, 3H), 8.11 (d, J = 5 Hz, 1H), 8.00 (d, J = 5 Hz, 1H), 7.60 (t, J = 7.5 Hz, 1H), 7.19 (d, J = 5 Hz, 1H), 4.64 (s, 3H), 2.63 (s, 3H).
[0049] Example 4-11: 6-Dimethylamino-2-[2-(8-Hydroxyquinolin-5-yl)-vinyl]-l- methylquinolinium trifluoromethanesulfonate (CPD5259)1H NMR (500 MHz, DMSO-d3); δ(ppm): 9.10 (d, J = 5 Hz, 1H), 8.94 (s, 1H), 8.69 (m, 2H), 8.42 (d, J = 10 Hz, 1H), 8.62 (d, J = 10 Hz, 1H), 7.88-7.76 (m, 3H), 7.72 (m, 4H), 7.23 (d, J = 10 Hz, 1H), 6.67 (d, J = 10 Hz, 1H), 4.49 (s, 3H), 3.14 (s, 6H); Mass: 356 (M + 1, free base).
[0050] Example 4-12: 6-Hydroxymethyl-2-[2-(8-Hydroxyquinolin-5-yl)-vinyl]-l- methylquinolinium trifluoromethanesulfonate (CPD5260)'H NMR (500 MHz, DMSO-d3); δ(ppm): 9.15 (d, J = 10 Hz, 1H), 9.04 (d, J = 10 Hz, 1H), 8.97 (d, J = 5 Hz, 1H), 8.85 (m, 2H), 8.52 (m, 2H), 8. 26 (s, 1H), 8.08 (d, J = 10 Hz, 1H), 7.92 (d, J = 15 Hz, 1H), 7.76 (dd, J = 5, 10 Hz, 1H), 7.29 (d, J = 10 Hz, 1H), 4.80 (s, 2H), 4.58 (s, 3H); Mass: 343 (M + 1, free base).
[0051] Example 4-13: 2-[2-(8-Hydroxyquinolin-5-yl)-vinyl]-6-methoxy-l- methylquinolinium trifluoromethanesulfonate (CPD5263)'H NMR (500 MHz, DMSO-d3); δ(ppm): 9.13 (d, J = 10 Hz, 1H), 8.97 (d, J = 5 Hz, 1H), 8.90 (d, J = 10 Hz, 1H), 8.82 (s, 1H), 8.79 (d, J = 10 Hz, 1H), 8.48 (d, J = 10 Hz, 2H),7.88 (d, J = 15 Hz, 1H), 7.80 (s, 2H), 7.76 (dd, J = 5, 10 Hz, 1H), 7.28 (d, J = 5 Hz, 1H), 4.56 (s, 3H), 4.00 (s, 3H); Mass: 343 (M + 1, free base).
[0052] Example 4-14: 2-[2-(8-Hydroxyquinolin-5-yl)-vinyl]-l,6-dimethylquinolinium trifluoromethanesulfonate (CPD5264)'H NMR (500 MHz, DMSO-d3); δ(ppm): 9.00 (d, J = 10 Hz, 1H), 8.74 (s, 1H), 8.67 (d, J = 15 Hz, 1H), 8.44 (t, J = 10 Hz, 2H) 8.28 (d, J = 10 Hz, 1H), 7.95 (s, 1H), 7.89 (d, J = 5 Hz, 1H), 7.61 (dd, J = 5, 10 Hz, 1H), 7.44 (d, J = 10 Hz, 1H), 7.22 (d, J = 10 Hz, 1H), 6.79 (d, J = 10 Hz, 1H), 4.17 (s, 3H), 2.57 (s, 3H); Mass: 327 (M + 1, free base).
[0053] Example 4-15: 6-Hydroxymethyl-2-[2-(8-Hydroxyquinolin-4-yl)-vinyl]-l- methylquinolinium trifluoromethanesulfonate (CPD5265)1H NMR (500 MHz, DMSO-d3); δ(ppm): 9.98 (s, 1H), 9.23 (d, J = 10 Hz, 1H), 9.01 (d, J = 2 Hz, 1H), 8.83 (d, J = 5 Hz, 1H), 8.74 (d, J = 15 Hz, 1H), 8.61 (d, J = 10 Hz, 1H), 8. 36 (s, 1H), 8.23-8.15 (m, 2H) 8.15 (d, J = 5 Hz, 1H), 8.01 (d, J = 5 Hz, 1H), 7.60 (t, J = 10 Hz, 1H), 7.20 (d, J = 10 Hz, 1H), 4.83 (s, 2H), 4.66 (s, 3H); Mass: 343 (M + 1, free base).
[0054] Example 4-16: 6-Cyano-2-[2-(8-hydroxyquinolin-5-yl)-vinyl]-l-methylquinolinium trifluoromethanesulfonate (CPD5272)1H NMR (500 MHz, DMSO-d3); δ(ppm): 9.19 (d, J = 10 Hz, 1H), 9.03-8.95 (m, 4H),8.89 (s, 1H), 8.67 (d, J = 10 Hz, 1H), 8.62 (d, J = 10 Hz, 1H), 8.47 (d, J = 5 Hz, 1H), 7.94 (d, J = 15 Hz, 1H), 7.80 (dd, J = 5, 10 Hz, 1H), 7.29 (d, J = 5 Hz, 1H), 4.55 (s, 3H); Mass: 338 (M + 1, free base).
[0055] Example 4-17: 5 -Chloro-2-[2-(8-hydroxyquinolin-5-yl)-vinyl]-l-methylquinolinium trifluoromethanesulfonate (CPD5273)'H NMR (500 MHz, DMSO-d3); δ(ppm): 9.16 (d, J = 10 Hz, 1H), 9.05 (d, J = 5 Hz, 1H), 8.97 (m, 2H), 8.57 (d, J = 5 Hz, 1H), 8.53 (d, J = 10 Hz, 1H), 8.11 (m, 2H), 7.93 (d, J = 15 Hz, 1H), 7.78 (dd, J = 5, 10 Hz, 1H), 7.29 (d, J = 10 Hz, 1H), 4.57 (s, 3H).
[0056] Example 4-18: 2-[2-(8-Hydroxyquinolin-5-yl)-vinyl]-l-methy-6- trifluoromethyllquinolinium trifluoromethanesulfonate (CPD5286)'HNMR (500 MHz, DMSO-d3); δ(ppm): 9.19 (dd, J = 5, 10 Hz, 1H), 9.12 (d, J = 10 Hz, 1H), 9.03 (m, 1H), 9.01 (d, J = 10 Hz, 1H), 8.98 (d, J = 5 Hz, 1H), 8.84 (s, 1H), 8.73 (d, J = 10 Hz, 1H), 8.62 (d, J = 10 Hz, 1H), 8.43 (d, J = 10 Hz, 1H), 7.97 (d, J = 15 Hz, 1H), 7.80 (dd, J = 5, 10 Hz, 1H), 7.31 (d, J = 10 Hz, 1H), 4.60 (s, 3H).
[0057] Example 4-19: 2-[2-(8-Hydroxyquinolin-5-yl)-vinyl]-l,5-dimethylquinolinium trifluoromethanesul fonate (CPD 5287)'H NMR (500 MHz, DMSO-d3); δ(ppm): 9.14 (d, J = 10 Hz, 1H), 9.05 (d, J = 10 Hz, 1H), 8.86 (d, J = 15 Hz, 1H) 8.83 (d, J = 10 Hz, 1H), 8.51 (d, J = 10 Hz, 1H), 8.38 (d, J = 10 Hz, 1H), 8.04 (dd, J = 5, 10 Hz, 1H), 7.92 (d, J = 15 Hz, 1H), 7.77 (m, 1H), 7.28 (d, J = 5 Hz, 1H), 4.57 (s, 3H), 2.84 (s, 3H).
[0058] Example 4-20: 6-Dimethylamino-2-[2-(8-Hydroxyquinolin-4-yl)-vinyl]-l- methylquinolinium trifluoromethanesulfonate (CPD5338)'H NMR (500 MHz, DMSO-d3); δ(ppm): 9.94 (s, 1H), 8.98 (d, J = 5 Hz, 1H), 8.82 (d, J = 10 Hz, 1H), 8.62 (m, 2H), 8.41 (d, J = 10 Hz, 1H), 8.00 (d, J = 10 Hz, 1H), 7.79 (dd, J = 5, 10 Hz, 1H), 7.58 (t, J = 7.5 Hz, 1H), 7.32 (d, J = 5 Hz, 1H), 7.18 (d, J = 10 Hz, 1H), 4.58 (s, 3H), 3.17 (s, 6H); Mass: 356 (M + 1, free base).
[0059] Example 4-21: l-Ethyl-2-[2-(8-Hydroxyquinolin-5-yl)-vinyl]-quinolinium iodide (CPD5339)1H NMR (500 MHz, DMSO-d3); δ(ppm): 9.01 (d, J = 5 Hz, 1H), 8.77 (s, 1H), 8.57 (s, 1H), 8.46 (d, J = 10 Hz, 1H), 8.35 (s, 1H), 8.11 (m, 2H), 7.90 (s, 1H), 7.62 (s, 2H), 7.19 (s, 1H), 6.82 (s, 1 H), 4.80 (br q, 2H), 1.58 (br t, 3H).
[0060] Example 4-22: 2-[2-(8-Hydroxyquinolin-5-yl)-vinyl]-l,4-dimethylquinolinium trifluoromethanesulfonate (CPD5341)1H NMR (500 MHz, DMSO-d3); δ(ppm): 9.15 (d, J = 10 Hz, 1H), 9.01 (d, J = 10 Hz, 1H), 8.83 (d, J = 15 Hz, 1H) 8.56 (d, J = 5 Hz, 1H), 8.51 (d, J = 10 Hz, 1H), 8.38 (d, J = 10 Hz, 1H), 8.04 (dd, J = 5, 10 Hz, 1H), 7.92 (d, J = 15 Hz, 1H), 7.77 (m, 1H), 7.28 (d, J = 5 Hz, 1H), 4.57 (s, 3H), 2.84 (s, 3H).
[0061] Example 4-23: 2-[2-(8-Hydroxyquinolin-4-yl)-vinyl]-6-methoxy-l- methylquinolinium trifluoromethanesulfonate (CPD5344)1H NMR (500 MHz, DMSO-d3); δ(ppm): 9.97 (s, 1H), 9.07 (d, J = 10 Hz, 1H), 8.99 (d, J = 5 Hz, 1H), 8.80 (d, J = 5 Hz, 1H), 8.72 (d, J = 15 Hz, 1H), 8.58 (d, J = 10 Hz, 2H),8.20 9M, 2H), 8.01 (d, J = 10 Hz, 1H), 7.89 (m, 2H), 7.59 (t, J = 7.5 Hz, 1H), 7.20 (d, J = 5 Hz, 1H), 4.64 (s, 3H), 4.03 (s, 3H).
[0062] Example 4-24: 2-[2-(8-Hydroxyquinolin-4-yl)-vinyl]-l,5-dimethylquinolinium trifluoromethanesul fonate (CPD 5345)'H NMR (500 MHz, DMSO-d3); δ(ppm): 9.99 (s, 1H), 9.26 (d, J = 10 Hz, 1H), 9.01 (d, J = 2 Hz, 1H), 8.81 (d, J = 10 Hz, 1H) 8.76 (d, J = 15 Hz, 1H), 8.48 (d, J = 10 Hz, 1H),8.20 (m, 2H), 8.14 (t, J = 10 Hz, 1H), 8.00 (d, J = 5, 10 Hz, 1H), 7.87 (d, J = 10 Hz, 1H), 7.60 (t, J = 7.5 Hz, 1H), 7.20 (d, J = 10 Hz, 1H), 4.65 (s, 3H), 2.95 (s, 3H).
[0063] Example 4-25: 2-[2-(8-Hydroxyquinolin-4-yl)-vinyl]-8-methoxy-l- methylquinolinium trifluoromethanesulfonate (CPD5346)1H NMR (500 MHz, DMSO-d3); δ(ppm): 10.00 (s, 1H), 9.16 (d, J = 10 Hz, 1H), 9.01 (d, J = 2 Hz, 1H), 8.77 (m, 2H), 8.16 (d, J = 5 Hz, 1H), 8.10 (d, J = 15 Hz, 1H), 8.01 (d, J = 5 Hz, 1H), 7.95 (m, 2H), 7.80 (m, 1H), 7.60 (t, J = 7.5 Hz, 1H), 7.20 (d, J = 10 Hz, 1H), 4.67 (s, 3H), 4.13 (s, 3H).
[0064] Example 4-26: 2-[2-(8-Hydroxyquinolin-4-yl)-vinyl]-l,6.7-trimethylquinolinium trifluoromethanesulfonate (CPD5349)'H NMR (500 MHz, DMSO-d3); δ(ppm) : 9.98 (s, 1H), 9.06 (d, J = 10 Hz, 1H), 9.00 (d, J = 1 Hz, 1H), 8.70 (m, 2H), 8.46 (s, 1H), 8.20 (m, 3H), 8.00 (d, J = 5 Hz, 1H) 7.59 (t, J = 7.5 Hz, 1H), 7.20 (d, J = 5 Hz, 1H), 4.62 (s, 3H), 2.64 (s, 3H), 2.54 (s,3H).
[0065] Example 4-27: 2-[2-(8-Hydroxyquinolin-5-yl)-vinyl]-l,6.7-trimethylquinolinium trifluoromethanesulfonate (CPD5350)'H NMR (500 MHz, DMSO-d3); δ(ppm): 9.10 (d, J = 5 Hz, 1H), 8.96 (d, J = 5 Hz, 1H), 8.88 (d, J = 10 Hz, 1H), 8.77 (d, J = 15 Hz, 1H), 8.72 (d, J = 5 Hz, 1H), 8.48 (d, J = 5 Hz, 1H), 8.06 (s, 1H), 7.89 (d, J = 15 Hz, 1H) 7.75 (dd, J = 5, 10 Hz, 1H), 7.27 (d, J = 10 Hz, 1H), 4.54 (s, 3H), 2.60 (s, 3H), 2.51 (s,3H).
[0066] Example 4-28: 6-Ethoxy-2-[2-(8-Hydroxyquinolin-4-yl)-vinyl]-l-methylquinolinium trifluoromethanesulfonate (CPD5351)'H NMR (500 MHz, DMSO-d3); δ(ppm): 9.97 (s, 1H), 9.04 (d, J = 10 Hz, 1H), 9.00 (d, J = 5 Hz, 1H), 8.78 (d, J = 10 Hz, 1H), 8.70 (d, J = 15 Hz, 1H), 8.56 (d, J = 15 Hz, 1H),8.20 (m, 2H), 8.00 (d, J = 10 Hz, 1H) 7.88 (m, 2H), 7.59 (t, J = 7.5 Hz, 1H), 7.20 (d, J = 5 Hz, 1H), 4.63 (s, 3H), 4.31 (q, J = 5 Hz, 2H), 1.47 (t, J = 7.5 Hz, 3H).
[0067] Example 4-29: 6-Ethoxy-2-[2-(8-Hydroxyquinolin-5-yl)-vinyl]-l-methylquinolinium trifluoromethanesulfonate (CPD5352)'H NMR (500 MHz, DMSO-d3); δ(ppm): 9.12 (d, J = 10 Hz, 1H), 8.96 (d, J = 5 Hz, 1H), 8.88 (d, J = 10 Hz, 1H), 8.79 (m, 2H), 8.47 (m 2H), 7.89 (d, J = 15 Hz, 1H) 7.76 (m, 3H), 7.28 (d, J = 10 Hz, 1H), 4.56 (s, 3H), 4.28 (q, J = 5 Hz, 2H), 1.45 (t, J = 7.5 Hz, 3H).
[0068] Example 4-30: 2-[2-(8-Hydroxyquinolin-4-yl)-vinyl]-l,5.7-trimethylquinolinium trifluoromethanesulfonate (CPD5353)1H NMR (500 MHz, DMSO-d3); δ(ppm): 9.98 (s, 1H), 9.19 (d, J = 10 Hz, 1H), 9.01 (d, J = 5 Hz, 1H), 8.72 (t, J = 10 Hz, 2H), 8.31 (s, 1H), 8.20 (dd, J = 5, 10 Hz, 2H), 8.00 (d, J = 10 Hz, 1H) 7.74 (s, 1H), 7.60 (t, J = 7.5 Hz, 1H), 7.20 (d, J = 5 Hz, 1H), 4.61 (s, 3H), 2.84 (s, 3H), 2.67 (s,3H).Example 5: Biochemical Assay for screening compounds against NS2B-NS3 protease of Zika, Dengue and West Nile viruses (ZKV, DNV and WNV NS2B-NS3pro)
[0069] The purified individual NS2B-NS3pro of ZKV (2.4 nM), DNV (83.5 nM) and WNV (7.5 nM) were pre-incubated for 30 minutes at 37°C with the individual compounds at the indicated concentrations (1000-7.8 nM) in 90 pl 10 mM Tris-HCl pH 8.5, 1 mM CHAPS, 20% glycerol. DMSO (1%) served as a control. Benzoyl-Nle-Lys-Arg-Arg-MCA fluorogenic substrate (15 pM) was added in 10 pl of the same buffer. The reaction velocity was monitored continuously at λex= 355 nm and λex= 460 nm in a POLARstar Omega fluorescent plate reader (BMG Labtech). All assays were performed in triplicate in a 96-well, F-bottom, Fluotrac, black microplate (Greiner Bio One. Cat #655076). The IC50 values were calculated as the compound concentrations giving half-maximum inhibition of NS2B-NS3pro activity. GraphPad Prism was used as the curve fitting software. The results are provided in Table 1.
[0070] As shown in Table 1 and FIGs. 1-3, Compounds of Formula I and II show significant inhibition of NS2B-NS3pro activity in all Zika, Dengue, West Nile Viruses.Table 1: Inhibition of NS2B-NS3 Protease of Zika, Dengue and West Nile Viruses
Claims
CLAIMS1. A compound having Formula I or II, a pharmaceutically acceptable salt, N-oxides, tautomers, hydrates, isotopes, or prodrugs thereof, or a mixture thereof:Formula I Formula II wherein,R is C1to C12alkyl, C2to C12alkenyl, C2to C12alkynyl, C2to C12substituted alkyl, C2to C12substituted alkenyl, or C2to C12substituted alkynyl;R1and R2 are one of more groups independently selected from H, halo, alkyl, alkoxy, cyano, nitro, CO2R4, C(0)NR4R5, -CH=NR4, -NR4R5, or -N=R6, wherein,R4and R5are independently C1to C12alkyl, C2to C12alkenyl, C2to C12alkynyl, C2to C12substituted alkyl, C2to C12substituted alkenyl, C2to C12substituted alkynyl, or -NR4R5is heterocyclic, substituted heterocyclic and cyclic C2to C7heteroalkylene or substituted cyclic C2to C7heteroalkyne;R6is hydrogen, oxygen, C1to C12alkyl or C1to C12substituted alkyl;R3is H or C1to C2alkyl; andX is a halide, alkyl sulfonate, trihaloalkyl sulfonate, aryl sulfonate, or alkylsulfate.
2. The compound of claim 1, whereinR is C1to C7alkyl, C7to C18phenylalkyl;R1and R2 are one of more groups independently selected from H, F, Cl, Br, nitro, amine, CH3, OMe, CF3, OCF3, C1to C12alkyl, C1to C12alkenyl, carboxylic acid or ester thereof;R4and R5are independently, C1to C6alkyl, or C1to C6substituted alkyl; andX is a halide, methanesulfonate, trifluoromethanesulfonate, toluenesulfonate, or methylsulfate.
3. The compound of claim 1 or 2, wherein -NR4R5is independently a substituted or unsubstituted heterocyclic ring of 4 to 8 atoms, comprising 0 to 3 heteroatoms selected from N, O or S, C=O, or C=NR6.
4. The compound of claim 3, wherein the heterocyclic ring for -NR4R5includes, but not limited to, morpholine-4-yl, piperazine- 1-yl, 3 -oxopiperazine- 1-yl, and 1 -homopiperazine- lyl.
5. The compound of claim 1, whereinR is C1to C12alkyl;R1and R2 are one of more groups independently selected from H, halo, alkyl, alkoxy, or cyano;R3is H or C1to C2alkyl;R4and R5are independently H or C1to C12alkyl; andR6is hydrogen or oxygen.
6. The compound of claim 1, whereinR is CH3, CH2CH3, CH2CH2CH3or CH(CH3)2;RI and R2 are one of more groups independently selected from H, fluoro, chloro, CH3, CH2CH3, CH2CH2CH3or CH(CH3)2, OCH3, OCH2CH3, OCH2CH2CH3or OCH(CH3)2, or CN;R3is H, CH3, CH2CH3, CH2CH2CH3or CH(CH3)2;R4and R5are independently H, CH3, CH2CH3, CH2CH2CH3or CH(CH3)2; andR6is oxygen.
8. A pharmaceutical composition comprising a compound of any one of claims 1-7.
9. A method of preparing the compound of claim 1, comprising: reacting a compound of Formula 3 and R-X to form a compound of Formula 4; reacting the compound of Formula 4 with a compound of Formula 5 to form a compound of Formula I of claim 1, or reacting the compound of Formula 4 with a compound of Formula 6 to form a compound of Formula II of claim 1 :wherein all variables are as defined in claim 1.
10. The method of claim 9, whereinR is C1to C12alkyl, C2to C12alkenyl, C2to C12alkynyl, C2to C12substituted alkyl, C2to C12substituted alkenyl, or C2to C12substituted alkynyl;R1and R2 are one of more groups independently selected from H, halo, alkyl, alkoxy, cyano, nitro, CO2R4, C(O)NR4R5, -CH=NR4, -NR4R5, or -N=R6, wherein,R4and R5are independently C1to C12alkyl, C2to C12alkenyl, C2to C12alkynyl, C2to C12substituted alkyl, C2to C12substituted alkenyl, C2to C12substituted alkynyl, or -NR4R5is heterocyclic, substituted heterocyclic and cyclic C2to C7heteroalkylene or substituted cyclic C2to C7heteroalkyne;R6is hydrogen, oxygen, C1to C12alkyl or C1to C12substituted alkyl;R3is H or C1to C2alkyl; andX is a halide, alkyl sulfonate, trihaloalkyl sulfonate, aryl sulfonate, or alkylsulfate.
11. The method of claim 9, whereinR is C1to C7alkyl, C7to C18phenylalkyl;R1and R2 are one of more groups independently selected from H, F, Cl, Br, nitro, amine, CH3, OMe, CF3, OCF3, C1to C12alkyl, C1to C12alkenyl, carboxylic acid or ester thereof;R4and R5are independently, C1to C6alkyl, or C1to C6substituted alkyl; andX is a halide, methanesulfonate, trifluoromethanesulfonate, toluenesulfonate, or methylsulfate.
12. The method of claim 9, whereinR is C1to C12alkyl;R1and R2 are one of more groups independently selected from H, halo, alkyl, alkoxy, or cyano;R3is H or C1to C2alkyl;R4and R5are independently H or C1to C12alkyl; andR6is hydrogen or oxygen.
13. The method of claim 9, whereinR is CH3, CH2CH3, CH2CH2CH3or CH(CH3)2;RI and R2 are one of more groups independently selected from H, fluoro, chloro, CH3, CH2CH3, CH2CH2CH3or CH(CH3)2, OCH3, OCH2CH3, OCH2CH2CH3or OCH(CH3)2, or CN;R3is H, CH3, CH2CH3, CH2CH2CH3or CH(CH3)2;R4and R5are independently H, CH3, CH2CH3, CH2CH2CH3or CH(CH3)2; andR6is oxygen.
14. A method of treating and / or reducing the risk of a flavivirus infection in a subject comprising administering a composition comprising the compound of any one of claims 1-7 or a pharmaceutical composition comprising the compound of any one of claims 1-7, to a subject in need thereof.
15. The method of claim 14, wherein the flavivirus is selected from the group consisting of West Nile Virus (WNV), Zika Virus (ZKV), Dengue Virus (DNV), Yellow Fever Virus (YFV), Japan encephalitis virus (JEV), and combinations thereof.
16. The method of claim 14, wherein the flavivirus is selected from the group consisting of WNV, ZKV, DNV, and combinations thereof.
17. The method of claim 14, wherein the flavivirus is the WNV.
18. The method of claim 14, wherein the flavivirus is the ZKV.
19. The method of claim 14, wherein the flavivirus is the DNV.
20. The method of claim 14, wherein the flavivirus is DNV serotype DEN-1, DNV serotypeDEN-2, DNV serotype DEN-3, or DNV serotype DEN-4.
21. The method of any one of claims 14-20, wherein the pharmaceutical composition is a tablet or liquid.
22. The method of any one of claims 14-21, wherein the compound or pharmaceutical composition is administered to the subject before, during, and / or after traveling to an area susceptible to risk of a flavivirus infection and / or where flaviviruses are present.
23. The method of any one of claims 14-22, wherein the compound or pharmaceutical composition is administered orally or intravenously.
Citation Information
Patent Citations
Quinolinium dyes with fluorinated counter anion for dye sensitized solar cells
US20150108415A1
